Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of Sales Force Post-Allos Therapeutics Acquisition in Order to Enhance Presence in U.S. Market

Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of Sales Force Post-Allos Therapeutics Acquisition in Order to Enhance Presence in U.S. Market

<0> Spectrum PharmaceuticalsShiv Kapoor, 702-835-6300Vice President, Strategic Planning & Investor Relations </0>

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the Company is undertaking a strategic strengthening of its sales force in the U.S. The Company will implement a structure of six geographic regions, with each regional manager empowered to align sales resources and tailor promotional and other physician and patient support initiatives to meet our customers’ needs. The realignment of existing resources will result in a significantly greater hematology and oncology footprint, an increased promotional reach, and more efficient physician engagement.

Ken Keller, Executive Vice President, Chief Operating Officer of Spectrum Pharmaceuticals, Inc., commented, “As Spectrum’s oncology portfolio expands, it is essential we continue to build and grow our infrastructure and capabilities. With the recent addition of FOLOTYN through the acquisition of Allos, we have the opportunity to increase our investment in both the sales force and promotional support to effectively manage our product portfolio.”

Mr. Keller continued, "The new structure will allow our sale force to effectively promote all three products, resulting in a significant increase in share of voice. Synergies will also result because ZEVALIN and FOLOTYN are marketed to the same physicians. The realignment of commercial resources will result in a largely customer-facing commercial organization, keeping with Spectrum’s lean, cost-efficient business model. Additionally, we believe this structure will allow us to effectively and efficiently add more oncology products in the future."

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market three oncology drugs ─ FUSILEV (levoleucovorin) for Injection in the U.S.; FOLOTYN (pralatrexate injection), also marketed in the U.S.; and ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at .

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.